The Pharmacoeconomics of Managing Acute Agitation in the Emergency Department

What Do We Know and How Do We Approach It?

Esther W Chan; David McD Taylor; Jonathan C Knott; Danny Liew; David CM Kong


Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(5):589-595. 

In This Article

Expert Commentary

There is a lack of pharmacoeconomic studies in the area of acute agitation management in the ED setting and the inherent difficulties in conducting such studies need to be overcome. These difficulties include the limited availability of clinical probability data from clinical trials and the accessibility of adequately categorized dollar expenditure data on ED hospitalization from local or international data sources. Access to such data, however, depends on the facilitation of relevant robust clinical trials and the reporting strategies of institutional decision costing units, respectively. Using practical (pragmatic) clinical trial designs with real-life cost modeling is another means to obtain cost data that avoids potential biases associated with traditional ('per protocol') clinical trial design.

Furthermore, the modes of analysis, the use of a decision-analytic model, integration into RCTs, study perspective, sources (and the availability) of cost data and sensitivity analyses are important considerations when conducting pharmacoeconomic analyses for management of acute agitation in ED setting.